Clinical Trial Update: Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects [Phase 2, Phase 3]

View source ↗

Summary

The document reports safety and tolerability results from a rollover Phase 2/Phase 3 trial of tipranavir boosted with ritonavir in HIV-1–infected subjects.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Aptivus (tipranavir)
• Norvir (ritonavir)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: HIV Infections | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2009-07-16